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Abstract
Background: Epithelial-to-mesenchymal transition (EMT) has recently been implicated in the initiation and progression of
renal cell carcinoma (RCC). Some mRNA gene expression studies have suggested a link between the EMT phenotype and
poorer clinical outcome from RCC. This study evaluated expression of EMT-associated proteins in RCC using in situ
automated quantitative analysis immunofluorescence (AQUA) and compared expression levels with clinical outcome.
Methods/Principal Findings: Unsupervised hierarchical cluster analysis of pre-existing RCC gene expression array data
(GSE16449) from 36 patients revealed the presence of an EMT transcriptional signature in RCC [E-cadherin high/SLUG low/
SNAIL low]. As automated immunofluorescence technology is dependent on accurate definition of the tumour cells in
which measurements take place is critical, extensive optimisation was carried out resulting in a novel pan-cadherin based
tumour mask that distinguishes renal cancer cells from stromal components. 61 patients with ccRCC and clinical follow-up
were subsequently assessed for expression of EMT-associated proteins (WT1, SNAIL, SLUG, E-cadherin and phospho-b-
catenin) on tissue microarrays. Using Kaplan-Meier analysis both SLUG (p=0.029) and SNAIL (p=0.024) (log rank Mantel-
Cox) were significantly associated with prolonged progression free survival (PFS). Using Cox regression univariate and
multivariate analysis none of the biomarkers were significantly correlated with outcome. 14 of the 61 patients expressed the
gene expression analysis predicted EMT-protein signature [E-cadherin high/SLUG low/SNAIL low], which was not found to
be associated to PFS when measured at the protein level. A combination of high expression of SNAIL and low stage was
able to stratify patients with greater significance (p=0.001) then either variable alone (high SNAIL p=0.024, low stage
p=0.029).
Conclusions: AQUA has been shown to have the potential to identify EMT related protein targets in RCC allowing for
stratification of patients into high and low risk groups, as well the ability to assess the association of reputed EMT signatures
to progression of the disease.
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Introduction
Renal cell carcinoma (RCC) is the most deadly all the urological
malignancies [1]. In the UK 8,228 cases were diagnosed in 2007
and there were 58,240 new cases in the USA in 2008 [2]. The
reported incidence of RCC is increasing at a rate of 2.5% though
partially because of serendipitous identification due to improved
imaging techniques [3]. Localised and locally advanced tumours
are typically treated with nephrectomy; however, in 20–40% of
cases the disease will recur [4] and currently there is no curative
treatment for metastatic RCC. RCC is not a single disease entity
but a heterogeneous collection of cancers which arise in the
kidney, each driven by different genes and pathways [5,6]. In
addition, each cancer shows different clinical and pathological
features, with distinct patterns of origin within the nephron, local
invasion, and distant metastases [7]. Such complexity is thought to
be one of the reasons accounting for the low level of success in the
treatment of metastatic RCC [8].
The most common histological subtype of RCC is clear cell
RCC (ccRCC) which accounts for 70–80% of sporadic cases [9].
Loss-of-function mutations of the von Hippel Lindau (VHL)
tumour suppressor gene occur in at least two-thirds of sporadic
ccRCC cases [10], as well as accounting for hereditary ccRCC.
Even within ccRCC, subgroups based on gene expression clusters
associated with differential prognostic outcomes, have been
identified [11,12,13] allowing for the potential to study ccRCC
in greater detail.
In common with some other cancers epithelial-to-mesenchymal
transition (EMT) has been identified as potentially playing a
significant role in RCC [11,14,15]. EMT which is well
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1characterised in embryogenesis and wound healing, and has also
been linked to pathogenesis and tumour invasion [16]. Tun et al
proposed a model for RCC pathogenesis in which the develop-
ment biological process, mesenchymal-to-epithelial transition
(MET), is reversed resulting in EMT and dedifferentiation [15].
MET is the process by which the kidney, which is mesenchymal in
origin, develops. In addition, Brannon et al used consensus
clustering of gene expression data to show that ccRCC could be
divided into two subtypes with opposing EMT phenotypes, with
prognosis being poorer for the EMT phenotype [11]. The work by
Brannon and colleagues supported a previous study which found
that the activation of a wound healing gene expression signature in
ccRCC was associated with the features of EMT and a poorer
survival in ccRCC patients [14].
The identification of genes of interest related to EMT in ccRCC
pathogenesis allows for the translation of such genetic targets into
proteins of interest for use in the development of clinically relevant
tests. Despite the wide range of protein biomarkers available for
the study of ccRCC [8,17] there is a lack of published data on the
use of protein expression in relation to EMT in ccRCC.
Immunohistochemistry (IHC) is a key molecular pathology
technique used in diagnosis, prognosis and prediction of treatment
outcomes in RCC in the clinic. However, classical IHC itself is
only semi-quantitative at best. The recent development of
automated quantitative analysis (AQUA) of immunofluorescence
has allowed accurate and sensitive in situ protein quantification of
protein levels [18]. Despite the increasing use of AQUA for the
study of prognostic and predictive biomarkers in other cancers
including breast, ovary, and melanoma [19,20], its use in the study
of ccRCC is scarce [21,22], most likely because many renal cancer
cells are negative for cytokeratins which are used in the other
epithelial cancers to precisely distinguish tumour cells from stroma.
In this study quantitative immunofluorescence was utilised for
the first time to test the hypothesis that EMT related protein
markers and a reputed EMT signature, selected following analysis
of published gene expression data and review of the literature, are
of prognostic significance in ccRCC in a population of ccRCC
patients.
Materials and Methods
Gene expression analysis of GE16449 dataset
DNA microarrays dataset accession number GS16449 [11],
which contained tumour samples from 36 patients with ccRCC
was downloaded from the Gene Expression Omnibus public
database repository. This dataset which is MIAME compliant was
generated using Agilent Whole Human Genome (4644 k) Oligo
Microarrays. Data was normalized using the robust multichip
average (RMA) technique. The probesets for EMT gene targets
used in this analysis are listed in Table S1. Transcript levels were
mean-centred and analyzed using unsupervised cluster analysis
(average linkage clustering, Spearman’s rank correlation distance
metric) to establish relationships between the transcripts.
Study population and design
The study population consisted of 61 formalin-fixed, paraffin-
embedded tumour samples from patients with ccRCC who
underwent either partial or radical nephrectomy for suspected
RCC at the Department of Urology, Western General Hospital,
Edinburgh between 2001 and 2003. The study was approved
by the Lothian Research Ethics Committee (08/S1101/41). No
informed consent (written or verbal) was obtained for use of
retrospective tissue samples from the patients within this study,
most of whom were deceased, since this was not deemed necessary
by the Ethics Committee, who waived the need for consent. All
samples were anonymised. Table 1 summarises the characteristics
of the study population. Progression free survival (PFS) was
calculated from the date of nephrectomy to the date of progression
of the RCC (diagnosed on cross-sectional imaging), or to the date
of last follow-up (censored).
Tissue microarray (TMA) construction
In brief, following H&E staining of representative tumour blocks
from all 61 patients, three replicate TMAs with core diameters of
0.6 mm were constructed using established techniques [23]. A
separate tissue microarray (TMA) was created from 18 ccRCC
samples for the purposes of tumour mask optimisation (Table S2).
Tumour Mask Optimisation
For each core, areas of tumour are differentiated from stroma
by creating an epithelial tumour mask. As the collection of target
antibodies chosen for study included those from mouse and from
rabbit, tumour masks complementary to both sets were needed.
The following antibodies were tested as part of the tumour mask
optimisations: pan-cadherin (Cell Signalling 4068, rabbit), cytokeratin
(CK; Dako Z0622, rabbit), HRP-streptavidin (Invitrogen 43-4323),
biotin (Dako E0464, rabbit), CK5/6/8/18 (Novocastra NCL-CK5/6/
8/18, mouse), CD10 (Novocastra NCL-CD10-270, mouse), RCC
(Novocastra NCL-RCC, mouse), EMA (Dako M0613, mouse), CK (Dako
M3515, mouse), vimentin (Sigma V6630, mouse), pan-cadherin (Sigma-
Aldrich C1821, mouse) and IL-15 (Abcam ab55282, mouse). Table S3
details antibody dilutions and antigen retrieval solutions employed.
Table 1. Clinicopathological characteristics of ccRCC patients
included in study TMA (n=61).
Characteristic
Number/
Variable %
Age Median (years) 65.4 N/A
Range (years) 28.1–86.3 N/A
Sex Female 23 37.7
Male 38 62.3
Grade 1 1 1.6
2 33 54.1
3 19 31.1
4 81 3 . 1
Nodal status at surgery Nx 48 78.7
N0 10 16.4
N1 1 1.6
N2 2 3.3
Metastatic status at surgery M0 49 80.3
M1 12 19.7
T Stage 1 24 39.3
2 12 16.4
3 23 41.0
4 2 3.3
Tumour Size (cm) Median 6.8 N/A
Range 3.0–16.5 N/A
RCC PFS (months) Median 8.9 N/A
Range 0.0–91.5 N/A
doi:10.1371/journal.pone.0031557.t001
EMT Associated Proteins in ccRCC
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assessed based on their ability to: (i) distinguish between tumour
and stromal areas, (ii) bind homogenously across the entire core,
and (iii) bind both cell membrane and cytoplasm.
Immunofluorescence
Immunofluorescence was performed using methods previously
described [24]. Briefly, 3 mm TMA slides were deparaffinized
and antigen retrieved by pressure cooking in either Sodium
Citrate buffer pH 6.0 or Tris-EDTA (TE) buffer pH 9.0 for
5 minutes, following which the TMA sections were blocked using
3% H2O2 and serum-free protein block. The slides were then
incubated for 1 hour at room temperature with the one of the
following monoclonal antibodies E-cadherin (BD Sciences,
610181) SLUG (LifespanBio, LS-C30318), SNAIL (Abcam,
ab17732), WT1 (Genetex, GTX15249) and phospho-b-catenin
(Cell Signalling, 9561). After treatment with the target
antibodies, TMA sections were incubated overnight at 4uCw i t h
pan-cadherin (Cell Signalling, 4068, 1:100) or a combination of
pan-cadherin (Sigma-Aldrich, C1821, 1:750) and CK5/6/8/18
(Novocastro, 6003168, 1:100) to mask tumour areas for rabbit
and mouse based target antibodies respectively (see results
section for details). TMA sections were subsequently incubated
for 1.5 hours with secondary antibodies: Alexa Fluor 555–
conjugated antibody (tumour mask) and horseradish peroxidase–
decorated dextran polymer backbone (EnVision, Dako) to
amplify the target protein. DAPI (49, 6-diamidino-2-phenylin-
dole) counterstain was used to visualise the nuclei and Cy-5-
tyramide used to detect target to allow compartmentalised
analysis of tissue sections. A summary of the experimental
conditions can be seen in Table 2.
AQUA automated image analysis
A detailed description of the AQUA methodology is available
elsewhere [24]. In brief, monochromatic images of each TMA
core were captured at 206 objective using an Olympus AX-51
epifluorescence microscope, and high-resolution digital images
were analyzed by the AQUAnalysis software. A binary epithelial
mask was created from the optimised tumour mask antibodies to
create an image of each TMA core. If the epithelium comprised
,5% of total core area, the core was excluded from analysis.
Similar binary masks were created for cytoplasmic and nuclear
compartments based on DAPI staining of nuclei. Target
expression was quantified by calculating the Cy5 fluorescent
signal intensity on a scale of 0 to 255 within each image pixel, and
the AQUA score was generated by dividing the sum of Cy5 signal
within the epithelial mask by the area of the cytoplasmic
compartment.
Statistical analysis methods
AQUA scores were initially averaged from replicate cores, and
mean centred for each array replicate. To reduce type I error that
can result from using the minimum p value method for
determining the cutpoint value for target expression in Kaplan-
Meier analysis [25] X-Tile was used; this allows determination of
an optimal cutpoint while correcting for the use of minimum p
statistics [26]. Overall survival was subsequently assessed by
Kaplan-Meier analysis with log rank for determining statistical
significance. As the continuous quantitative values were not
normally distributed non-parametric statistical analysis were
conducted. Multiple continuous, non-parametric variables were
compared with the Kruskal-Wallis test. To correct for the error
(Type I and II) due to multiple comparisons, significant P value
thresholds were corrected by using the Bonferroni Correction.
Univariate and multivariate analysis of biomarkers and clinico-
pathological variables was calculated using Cox regression
analysis. c indexes were calculated using ROC-AUC. All
calculations and analyses were two tailed where appropriate were
conducted using SPSS 14.0 for Windows (SPSS, Inc., Chicago, IL,
USA).
Results
Cluster analysis of ccRCC gene expression indicates the
existence of EMT and non-EMT phenotypes
Unsupervised hierarchical cluster analysis of the DNA micro-
array set accession number GS16449 [11] using the EMT relevant
probe sets listed in Table S1 identified the presence of two main
clusters: an ‘‘EMT cluster’’ (Cluster 1, Figure 1) with low
expression of CDH1 (E-cadherin), high expression of SNAI3
(SNAIL homolog 3) and high expression of SNAI2 (SNAIL
homolog 2, SLUG); and ‘‘non-EMT cluster’’ with reciprocal
expression of these genes (Cluster 2, Figure 1). Increased Wnt
signalling indicated by high CTNNB1 [b-catenin] expression and
high expression of WT1 were also observed in the EMT cluster. As
a result E-cadherin, SNAIL, SLUG, WT1 and phospho-b-catenin
proteins were selected for study at a protein level.
Tumour Mask Antibody Optimisation
In order to study the differential protein expressions of targets
identified from the microarray data it was necessary to establish
two tumour masking protocols, to complement the species in
which the target antibodies were raised. 738 AQUA images of 41
different tumour mask combinations used to treat the optimisation
TMA (including 18 ccRCC tissue samples) were analysed (Figure 2
illustrates examples). Of the antibodies tested a 1 in 100 dilution of
pan-cadherin (rabbit) (Figure 2d) best identified the tumour area
Table 2. The primary antibodies used during the study and the experimental conditions.
Target/Dilution Supplier Species
Antigen Retrieval
Solution
Tumour Mask (Antibody/
Dilution)
E-cadherin (1 in 1500) BD Sciences Mouse Sodium Citrate pH 6.0 Pan-cadherin (1 in 100)
SNAIL (1 in 800) Abcam Rabbit TE Buffer pH 9.0 Pan-cadherin and CK5/6/8/18 (1 in
750 and 1 in 100)
SLUG (1 in 1000) Lifespan Bio Rabbit TE Buffer pH 9.0
WT1 (1 in 100) Genetex Rabbit TE Buffer pH 9.0
phospho-b-catenin (1 in 25) Cell Signalling Rabbit TE Buffer pH 9.0
doi:10.1371/journal.pone.0031557.t002
EMT Associated Proteins in ccRCC
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epithelial tumour areas with minimal stromal binding. This was in
contrast to the mouse antibody vimentin which only bound stroma
(Figure 2a) or renal cell marker (RCC) which was non-selective,
binding both tumour and stromal areas equally (Figure 2b). The
best of the mouse derived antibodies was the pan-cadherin and
CK5/6/8/18 combination which allowed for selective binding to
theepithelial tumourarea with minimal stromalbinding(Figure2c).
These optimised antibodies were subsequently used to detected and
quantify the markers of interest on the TMA (Figure 3a–e).
Automated quantitative analysis of individual targets and
their association with clinicopathological parameters
Associations between the mean AQUA scores (Au) of the
individual protein targets and the following clinicopathological
variables were performed: grade, stage, histology, metastatic and
lymph node status (Kruskal–Wallis test; Table S4). Before
correction the only significant association was between E-
cadherin and tumour grade (p=0.032), however when corrected
for multiple comparisons only Grade 3 versus 4 was found to be
significant (p=0.004) at the recalculated significance level
Figure 2. Images of selected tumour masking options. (a) Vimentin (stroma stained) (b) Renal cell marker (stroma and epithelia stained) (c)
Pan-cadherin and CK5/6/8/18 (representative tumour mask for optimised mouse tumour mask) (d) Pan-cadherin (representative tumour mask for
rabbit tumour mask). White arrows indicate areas of non specific binding.
doi:10.1371/journal.pone.0031557.g002
Figure 1. Unsupervised hierarchical clustering of the GSE16449 microarray dataset, using the probe-sets of interest (Table S1).
Cluster 1 represents the group expressing the EMT signature and increased Wnt signalling, whereas the Cluster 2 illustrates the non-EMT cluster
group. (green=low expression, red=high expression).
doi:10.1371/journal.pone.0031557.g001
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significant correlations were detected when clinicopathological
variables were tested against the EMT biomarkers (Table 3).
SLUG SNAIL and E-Cadherin all gave c-indexes greater then
0.5 when tested for PFS indicating that the X-tile defined cut off
points were at least better then chance at patient stratification
(Table S5).
Association between clinicopathological variables and
survival
The effect of tumour stage and grade on PFS were assessed
(Figure 4). In the current study only stage was significantly
associated with PFS (p-value=0.015); increasing stage resulting in
decreasing PFS. When the significance association of stage with
PFS was corrected for multiple comparisons (p#0.008), only T1
Figure 3. AQUA quantitative image analysis. DAPI counterstain (blue) was used to identify nuclei, pan-cadherin antibody (rabbit) or a
combination of pan-cadherin and pan-cytokeratin antibodies (mouse) to identify infiltrating tumour cells (green) and Cy-5-tyramide for detectiono f
following target proteins (red) (a. E-cadherin, b. SNAIL, c. SLUG, d.WT1 and e. phospho-b-catenin).
doi:10.1371/journal.pone.0031557.g003
Table 3. Spearman’s Correlation Test of clinicopathological variables with EMT biomarkers.
Variables Slug Nuclear SNAIL Nuclear E-Cadherin Cytoplasm
Spearman’s rho Node Correlation Coefficient 0.043 20.043 0.022
Sig. (2-tailed) 0.742 0.742 0.869
Grade coded Correlation Coefficient 0.049 20.191 20.169
Sig. (2-tailed) 0.709 0.140 0.193
T stage Correlation Coefficient 20.199 20.130 20.009
Sig. (2-tailed) 0.125 0.317 0.943
Metastases Correlation Coefficient 20.194 20.194 0.018
Sig. (2-tailed) 0.133 0.133 0.893
n=61 for all analysis.
doi:10.1371/journal.pone.0031557.t003
EMT Associated Proteins in ccRCC
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significant. At the univariate level stage, grade and presence of
metastases were all significant indicators of progression free
survival (Table 4). Despite this only metastases remained
significant after multivariate analysis (Table 5).
Independent validation of EMT signature in ccRCC at the
protein level using AQUA
A cut-off point of the AQUA score that best predicted short and
long PFS for each of the individual targets was defined using the
minimum p-value method [26]. Generation of these cut-off points
enabled the association between protein expression and clinical
outcome to be established. As a result cut-off points for E-
cadherin, SNAIL and SLUG were used to divide AQUA scores
into either being low or high protein expression. Cut-off points for
WT1, phospho-b-catenin were not able to significantly divide
AQUA scores. These cut-off points were then used to create
Kaplan-Meier survival curves (Figure 5). SLUG (Figure 5c) and
SNAIL (Figure 5b) were found to be significant markers of PFS
(p=0.029 and p=0.024 (log rank Mantel-Cox test) respectively)
with high expression of these proteins being associated with
improved survival. In contrast E-cadherin (Figure 5a) did not
reach significance (p=0.051) and high expression was associated
with a poorer prognosis. The EMT biomarkers didn’t reach
significance using Cox regression after either univariate (Table 4)
or multivariate analysis (Table 5).
An EMT-protein signature defined as [E-cadherin high/SLUG
low/SNAIL low] derived from the gene expression data was
assessed for its ability to stratify patients into low and high risk
groups. Using this criterion 14 of the 61 ccRCC patient samples
were identified as showing the EMT phenotype. There was no
significant association between presence of the EMT-protein
signature and PFS (p=0.103, log-rank test; Figure 5d).
In an effort to improve the significance of individual biomarkers
and clinicopathological variables combinations of the indepen-
dently significant biomarkers, i.e. high expression of SLUG or
SNAIL, in addition to grade and stage dichotomised to either
being low (grade 1 or 2, stage 1 or 2) or high (grade 3 or 4, stage 3
or 4) were tested and analysed using the Kaplan Meier method
(Table 6) [27,28]. Of the combinations tested only low grade + low
stage (p=0.025) and low stage + high SNAIL (p=0.001) (Figure 6)
produced significant p values. Both of these combinations gave
more significant p values then the individual parameters alone,
with the combinations associated with improved progression free
survival.
Figure 4. Progression free survival (PFS) curves. (a) stage and (b) grade using Kaplan-Meier methods. Note that 13 patients were classed as
having 0 months PFS due to having metastatic disease at the time of nephrectomy.
doi:10.1371/journal.pone.0031557.g004
Table 4. Univariate Cox Regression analysis of
clinicopathological variables and EMT biomarkers against PFS.
Variables p value Hazard Ratio 95% CI for Hazard Ratio
Lower Upper
Grade 0.020* 1.818 1.100 3.004
Stage 0.012* 1.690 1.212 2.547
Node 0.102 3.515 0.779 15.859
Metastases 0.0002** 47.577 6.344 356.788
E-Cadherin
Cytoplasm
0.417 1.144 0.827 1.583
SNAIL Nuclear 0.081 0.511 0.240 1.086
Slug Nuclear 0.194 0.570 0.244 1.332
*Significant at p,0.05 level.
**Significant at p,0.001 level.
doi:10.1371/journal.pone.0031557.t004
Table 5. Multivariate Cox Regression Analysis of
clinicopathological variables and EMT biomarkers against PFS.
Variables p value Hazard Ratio
95% CI for Hazard
Ratio
Lower Upper
Grade 0.762 1.293 0.245 6.810
Stage 0.605 1.184 0.645 2.249
Node 0.407 1.240 0.746 2.062
Metastases 0.001* 33.114 3.949 277.665
E-Cadherin Cytoplasm 0.672 1.080 0.756 1.544
SNAIL Nuclear 0.657 0.809 0.316 2.067
Slug Nuclear 0.902 0.934 0.317 2.753
*Significant at p,0.05 level.
doi:10.1371/journal.pone.0031557.t005
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The current study describes the expression of EMT related
proteins in ccRCC patients using quantitative immunofluores-
cence AQUA technology. This study demonstrated detailed
optimisation of AQUA for use in RCC research. Although an
EMT signature was identified at the gene expression level, which
was in agreement with other published ccRCC EMT related gene
expression studies [11,14], no significant association was found
between presence of the EMT-protein signature and worse
prognosis in ccRCC patients. A combination of low stage and
high SLUG expression was associated with a good clinical
outcome of greater significance than either stage or SLUG
expression alone.
In the study we have defined a protocol for distinguishing
epithelial tumour cells in RCC from stroma. Unlike the majority
of previous AQUA studies in a number of different tumour types,
which incorporate cytokeratin in the tumour mask [22], the
current study used pan-cadherin antibodies as many RCC are
cytokeratin negative [29]. This ability to diversify from cytokeratin
antibodies in addition to being able to tailor the tumour mask to
the species in which the target antibodies have been raised
highlights the flexibility of AQUA as a system for studying protein
expression. A previous RCC study demonstrating AQUA used a
non-cytokeratin based tumour mask, specifically a vimentin/
EMA/CD10 combination [21]. In our experience the vimentin/
EMA/CD10 combination bound to both the stroma and epithelial
tumour area, unlike the optimal tumour masking strategies
developed following our optimisation strategy.
Recent RCC gene expression studies have implicated EMT in
RCC pathogenesis [11,14,15]. An inherent drawback of any gene
expression profiling technique is that, despite the high number of
potential targets available for study, steady-state levels of RNA are
not necessarily reflective of the final steady-state level of the
functional protein translation product of the mRNA [30]. In
contrast protein expression determinations by methods such as
AQUA give an accurate insight into the relative levels of the
selected proteins in any given study. Despite this no dedicated
protein expression studies of EMT in RCC exist. In the current
study, AQUA analysis was successful in the accurate detection of
EMT related proteins including E-cadherin, SLUG, SNAIL, WT1
and phospho-b-catenin in ccRCC. Of these proteins SLUG and
SNAIL were able to categorise patients into high and low risk for
PFS to a significant degree (p,0.05), warranting further study into
their potential use as putative prognostic protein markers in
ccRCC. The lack of the expected statistically significant
Figure 5. Survival curves based on AQUA protein expression cut-off points. (a) E-cadherin expression, (b) SNAIL expression, (c) SLUG
expression and (d) EMT phenotype versus progression free survival (PFS). Note that 13 patients were classed as having 0 months PFS due to
metastatic disease at the time of nephrectomy.
doi:10.1371/journal.pone.0031557.g005
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b-catenin may be due to relatively small number of patients
samples included in the study, but in any event suggest that these
measurements would be of limited value in a clinical setting for
individual patients.
Of particular interest was the significant association of high
expression of SLUG and SNAIL with improved survival and the
association of high E-cadherin expression with worse survival in
contrast to published data in RCC [11,14] and other cancers [31,32].
Despite this contradiction a recent similar RCC study investigating
the association of SLUG, SNAIL and E-cadherin in addition to other
markers with improved survival, showed that high SLUG was
significantly associated with improved survival, in contrast to SNAIL
which was negative associated with survival while E-cadherin
association wasn’t significant [33]. Of the 61 patient samples in the
current studies, 14 patients had the combined EMT-protein signature
of low E-cadherin and high expression of the E-cadherin repressors
SLUG and SNAIL. In contrastto other studies of EMT in ccRCC, in
the current study the EMT-protein signature was not associated with
a worse prognosis [11,14,15]., although this event has been identified
in a recent breast cancer study [34].
This study demonstrates the application and optimisation for
RCC of AQUA, a medium throughput method of in situ
quantification of protein using FFPE tissue. Furthermore, it has
been demonstrated that the transcription factors SNAIL and
SLUG are potential prognostic protein markers in ccRCC,
especially in combination with clinical parameters i.e. tumour
stage. The association of an EMT phenotype with poor clinical
outcome, previously demonstrated at the transcript level, has not
been confirmed by this protein study. A larger ccRCC sample set
along the lines described by Pepe et al [35] and the expansion of
the targets to include further EMT related proteins would be
necessary to further elucidate the role of EMT in ccRCC.
Figure 6. Progression free survival (PFS) curves based on combination of low stage and high SNAIL protein expression. Note that 13
patients were classed as having 0 months PFS due to metastatic disease at the time of nephrectomy.
doi:10.1371/journal.pone.0031557.g006
Table 6. Combinations of the clinicopathological variable
stage and grade (dichotomised into high and low) and high
expression of SLUG and SNAIL.
SLUG SNAIL Stage Grade
Number of Patients
Meeting Criteria.
Total=61
Log Rank
(Mantel-Cox)
p value
High 20 0.029*
High 44 0.024*
Low 25 0.029*
Low 27 0.036*
High High 18 0.082
High High Low Low 8 0.121
Low Low 22 0.025*
High High Low 13 0.235
High High Low 10 0.236
High Low 13 0.253
High Low 20 0.380
High Low 28 0.075
High Low 27 0.0008**
*Significant at p,0.05 level.
**Significant at p,0.001 level.
doi:10.1371/journal.pone.0031557.t006
EMT Associated Proteins in ccRCC
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